Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum.
Risa M HoffmanSean BrummelLauren ZiembaLameck ChinulaKatie McCarthyLee FairliePatrick Jean-PhilippeNahida ChakhtouraBen JohnstonChelsea KrotjeTeacler G NematadziraFrances NakayiwaVictoria NdyanabangiSherika HanleyGerhard TheronAvy ViolariEsau JoãoMario Dias Correa JuniorCristina Barroso HoferOranich NavanukrohLinda AurpibulNeetal NevrekarRebecca ZashRoger ShapiroJeffrey S A StringerJudith S CurrierPaul SaxShahin Lockmannull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Antepartum weight gain on DTG regimens was protective against adverse pregnancy outcomes traditionally associated with insufficient weight gain, supportive of guidelines recommending DTG-based ART for women starting ART during pregnancy. Interventions to mitigate postpartum weight gain are needed.